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Objectives: The aim of this study was to compare the relative compliance and the dermatological and pulmonary
outcomes when the Provox Luna system (Atos Medical, Malmö, Sweden) is added during the night to the usual tracheastoma
care of laryngectomized subjects.
Methods: This was a multicenter randomized crossover trial conducted in the Netherlands Cancer Institute, Erasmus
Medical Center, and Maastricht University Medical Center in The Netherlands. The study included 46 laryngectomized subjects
with prior heat and moisture exchanger (HME) and adhesive experience.
Results: A signiﬁcant improvement in the number of compliant individuals was found: Luna: n = 43 of 45 (96%); usual
care: n = 35 of 46 (76%), P = 0.02. The Luna period was associated with longer intervals of daily HME use (Luna 23.2 hours
[range: 15.6–24.0 hours], usual care [UC]: 21.5 hours [range: 6.0–24.0 hours], P = 0.003) and an increased frequency of skin
improvement overnight (Luna 3.9 days [standard deviation (SD)]: 7.0 days), Usual Care: 8.1 days ([SD: 10.8 days], P = 0.008).
Fifty-six percent (n = 26) of participants wanted to continue using the Provox Luna system at the conclusion of the study.
Conclusion: An improvement in compliance and skin recovery overnight was observed when the Provox Luna was added
to the usual adhesive and HME use. Therefore, there is utility in supplementing the usual post-total laryngectomy care with the
Provox Luna system at night, particularly in the setting of compliance concerns and in subjects who desire dermatological relief
overnight.
Key Words: Heat and moisture exchanger, total laryngectomy, tracheostoma, Provox Luna, skin irritation, HME compli-
ance, adhesives.
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INTRODUCTION
Anatomical changes that follow a total laryngectomy
(TLE) alter the normal physiology of the upper respira-
tory tract.1 Inspired air bypasses the upper airway due to
the placement of a permanent tracheostoma at the
base of the neck, impeding physiological upper airway
conditioning (warming, ﬁltration, and humidiﬁcation).2
Consequently, deﬁnitive open tracheostoma ventilation is
associated with marked histological changes to the tra-
cheal mucosa. This includes the loss of ciliated epithelial
cells and goblet cell hyperplasia,3,4 which impairs muco-
ciliary clearance.5,6
The increased incidence of chronic airway inﬂamma-
tion and pulmonary infections are known long-term
sequelae of prolonged impaired mucociliary clearance.7,8
Psychosocial complaints including reduced quality of
life, and increased rates of anxiety and depression9
accompany these subject-reported symptoms. Heat and
moisture exchangers (HMEs) are passive airway recon-
ditioning devices that are positioned at the opening of
the tracheostoma. HMEs retain heat and moisture in the
core media, thereby warming and humidifying inspired
air.10 Compliant HME use is associated with reduced
coughing, forced expectoration,11,12 external humidiﬁer/-
vaporizer use, and lower healthcare costs.13,14 These ﬁnd-
ings have been attributed to an improved tracheal
climate, particle ﬁltering, and increased respiratory
resistance.15,16
HME beneﬁts correlate with the duration of use.17
Although short intervals of nonuse (a few hours) have
failed to demonstrate signiﬁcant changes to HME
efﬁcacy,3 failure of compliant use of this device during
both the day and night is attributed with poor pulmonary
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outcomes.11,18,19 A large body of evidence showing a sig-
niﬁcant improvement in subject reported beneﬁts result-
ing from compliant HME use exists; however,
noncompliance ranges from 48% to 82% of subjects.11,20,21
Furthermore, approximately 20% of subjects report skin
irritation at the adhesive site and further discomfort while
sleeping with the HME device in place.17,22
Conventional HME devices and peristomal adhesives
contain inﬂexible synthetic materials that are thought to
inﬂuence comfort, compliance, and skin irritation. Atos Med-
ical (Malmö, Sweden) has developed the Provox Luna by
designing a hydrogel-based soft adhesive with soft silicon
housing in an effort to ameliorate these issues. Use of
hydrogel-based adhesives is widely documented elsewhere in
the body for wound management.23,24 These are glycerin- or
water-based materials that are thought to reduce irritation
at the site of contact to the skin via a cooling effect.23,24
Although hydrogel adhesion may be inferior adhesive prop-
erties to silicon glues, the Luna adhesive may be an alterna-
tive to improve comfort during the night and, consequently,
compliance and pulmonary complaints following TLE.
The aim of this clinical trial is to assess subject pref-
erence and compare the relative compliance of HME use
when the Provox Luna is added to a subject’s usual care
(UC) and to document the associated changes to subject-
reported symptoms.
MATERIALS AND METHODS
Subjects
Subjects were recruited at The Netherlands Cancer Institute,
the Erasmus Medical Center, and Maastricht University Medical
Center in The Netherlands. The multicenter study protocol was
approved by theMedical Research Ethics Committee of the Nether-
lands Cancer Institute and performed in compliance with ISO
14155: 2011 (E): Clinical Investigation of medical devices for
human subjects–Good clinical practice and the regional and
national regulations (The Netherlands Central Committee on
Research Involving Human Subjects-Centrale Commissie Mensge-
bonden Onderzoek, case number: NL59449.031.16). Following the
acquisition of informed consent, subjects were invited to participate
if they fulﬁlled the following criteria were over 18 years old, at least
3 months post-TLE, at least 6 weeks postradiotherapy, and had
experience with HME and adhesive use. Subjects were excluded on
the basis of prior medical problems prohibiting HME or adhesive
use, recurrent or metastatic disease, functional incapacity to insert
and remove an HME or adhesive independently, inability to under-
stand or provide informed consent, impaired cognitive ability, or
regular use of a cannula (e.g., LaryTube; AtosMedical).
A total of 53 subjects were recruited from Erasmus Medical
Center (n = 26), Maastricht University Medical Center (n = 15),
and The Netherlands Cancer Institute (n = 12) into the study from
January 2017 to October 2017. The mean subject age was 65 years
(range: 54–80 years). Male-to-female ratio was 46:7. Thirty-two
subjects received primary radiotherapy (RT) or chemoradiotherapy
(CRT) and a salvage laryngectomy; 19 received postoperative RT
or CRT; and two received no radiotherapy. Eight worked full time;
four worked part time; 27 were retired; 11 received incapacity ben-
eﬁts; and three had other nonspeciﬁc working conditions. Types of
voice prosthesis included Provox Vega (n = 18), Provox 2 (n = 19),
Provox ActiValve (n = 13), and those without voice prosthesis
(n = 3). HME use during the day at baseline was comprised of Pro-
vox XtraFlow (n = 31), Provox XtraMoist (n = 15), and Provox
FreeHands series (n = 6); and one subject used nothing. Forty-two
subjects reported using an HME every night. Eleven used an HME
infrequently and sometimes used a bib or cannula (e.g., LaryTube)
during the night. Subjects were instructed to continue their base-
line nighttime care routine during the UC period of the study and
to use the Provox Luna system at night during the Luna period of
the study. Further background clinical data of the initial 53 sub-
jects recruited into the study is reported in Table I.
TABLE I.
Clinical Characteristic Data of All Subjects Who Were Initially
Enrolled into the Study (n = 53).
Characteristic
Randomization (n)
Provox luna ﬁrst 27
Usual care ﬁrst 26
Age (years) at entry
Mean/median (range) 65.3/64 (54–80)
Post-TL (months)
Mean/median (range) 69.1/36 (4–294)
Gender (n)
Male 46
Female 7
Primary tumor location (n)
Larynx 46
Hypopharynx 6
Other 1
N status (n)
N0 38
N1 10
N2 5
Neck dissection (n)
Unilateral 8
Bilateral 26
None 19
Esophagectomy (n)
Conducted 4
None 49
Pharyngectomy (n)
Total 6
Partial 4
None 43
Reconstruction (n)
Jejunum 6
Pectoralis major 11
None 36
Chemoradiotherapy (n)
Preoperative RT 27
Preoperative CRT 5
Postoperative RT 18
Postoperative CRT 1
None 2
Provox Luna: Atos Medical, Malmö, Sweden.
CRT = chemoradiotherapy; N = node; RT = radiotherapy, TL = total
laryngectomy.
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Methods
The study was a multicenter randomized crossover trial in
design whereby subjects acted as their own control in order to limit
bias and provide a valid control interval. Subjects were randomized
into two groups using a variable block randomization method
(Castor EDC [electronic data capture]; Amsterdam, The Nether-
lands)25 beginning with the use of Provox Luna system during the
night or with their usual care for 28 days. The subjects were then
crossed over for a second period of 28 days. Formal evaluations
took place at the commencement, midpoint (at 28 days), and end of
the study. Study coordinators were in contact with subjects by
phone every week to ensure they were recording daily observation
in their diaries and to address any problems that had arisen. Stan-
dardized questionnaires were employed in the form of a case report
form (CRF) to obtain general clinical data and baseline HME/
adhesive use at the onset, subject experiences at the midway point,
and comparisons and ﬁnal thoughts in the ﬁnal evaluation. All sub-
jects were also given a diary and instructed to record the hours of
daily HME use, type of HME or alternative used during the night,
the number of episodes of disrupted sleep due to coughing every
night, the presence of skin irritation in the evening, and any skin
improvement overnight. Subjects were also supplied with Luna
HMEs, a supply of Luna adhesives, a shower cap, and additional
protective adhesive strips.
The primary outcome measure in this study was the overall
compliance of HME use. Compliant HME use was deﬁned as HME
use for at least 20 hours of every day in at least 24 days out of
28 days. Secondary outcomes included pulmonary and dermatologi-
cal effects, subject satisfaction, sleeping, and general quality of life.
The structured questionnaire CRF aimed to provide some further
insight into subject experiences and factors thatmay inﬂuence future
HME use. The EuroQol ﬁve-dimensions ﬁve-level (EQ-5D-5 L) ques-
tionnairewas also employed to compare quality-of-life outcomes. This
validated tool scores on ﬁve domains (mobility, self-care, daily activi-
ties, pain/discomfort, and anguish/depression) in a balanced health
state index. The EQ visual analogue scale (VAS) records the patient’s
self-rated health on an analogue visual scale. EQ-5D-5 L scores and
VAS were recorded at the start of the study, after 4 weeks of usual
care, and after 4 weeks of Provox LunaHMEuse.
Of the initial 53 subjects enrolled in the study, 26 subjects
were randomized to begin with the use of Provox Luna system dur-
ing the night, and 27 subjects began with UC, both for 28 days.
There were four dropouts (7.5%): two were due to recurrent meta-
static disease, and two were due to subjects’ revoked initial agree-
ment to participate in the second week of study. Among the
remaining 49 subjects, one had failed to record diary data, and two
subjects were later found to have never used an HME prior to the
study and thus failed to comply with the inclusion criteria. One
Luna period diary was lost during follow-up; thus, following exclu-
sion of these subjects, the ﬁnal analysis was comprised of 46 UC
period diaries (87%) and 45 Luna period diaries (85%) (Fig. 1).
Statistical Analysis
Statistical analysis was performed using the IBM SPSS
PC + 22.0 (SPSS Inc., Armonk, NY) statistical package. Where
applicable, collected data was presented with mean and median
calculations accompanied by associated standard deviations (SD)
and ranges. Collected data was assessed for normality with the
Kolmogorov Smirnov test. All categorical data was then analyzed
with a McNemar test (combined with a binomial test), and the
remaining data was analyzed using the paired Wilcoxon signed
ranks (WMPSR) or the Mann-Whitney test. Multiple compari-
sons of ordinal or interval data were made with the Kruskal-
Wallis test. Trends were analyzed with Pearson correlation (CC)
over the two HME periods. All statistical tests were two-tailed
and were evaluated with a 5% level of signiﬁcance. The statisti-
cal protocol for the study was approved by The Netherlands Can-
cer Center Medical Ethical Board.
RESULTS
Compliance
The number of compliant users differed signiﬁcantly
between the two periods (Luna: n = 43 of 45 [96%], UC:
n = 35 of 46 [76%], P = 0.02 McNemar test). A signiﬁcant
improvement in the hours of HME use per day (Luna
mean: 23.3 [SD: 1.4], median: 23.9 [range: 15.6–24.0]
hours, UC mean: 21.6 [SD: 4.3], median: 23.3 [range:
6.0–24.0] hours, P = 0.003 WMPSR) and the number of
compliant days overall (Luna mean: 27 [SD: 4.3], median:
28 [range: 0–28] days, UC mean: 22.5 [SD: 10.1], median:
28 [range: 0–28] days, P = 0.002 WMPSR) was observed
during the interval of Provox Luna use (Table II). All eight
subjects who had reported not using an HME every night
at baseline were noncompliant during the UC period (out
of 11 noncompliant subjects). Two of them were the non-
compliant subjects during the Luna period. Nine of the
11 subjects who were noncompliant HME users during
the UC period had compliant HME use during the Luna
period. In the Luna interval, 19 subjects reported longer
use of an HME during the day by a mean of 4.3 hours, and
nine subjects had shorter use by a mean of 0.6 hours.
No difference in the weekly mean hours of HME use
per day was established between separate weeks within the
Luna (P = 0.32, Friedman test) or UC period (P = 0.16,
Friedman test). Subjects who were randomized to begin
with Provox Luna use or UC versus those who ended with
Provox Luna use or UC, respectively, has statistically simi-
lar outcomes in all domains; hence, the order of product use
did not appear to impact outcomes.
Coughing
The overall mean number of disturbed sleep episodes
due to coughing per night did not differ between the UC
(mean: 0.50 [SD: 0.75, range: 0–2.6] episodes) and Luna
(mean: 0.49 [SD: 0.75, range: 0–2.6] episodes, P = 0.537
WMPSR) periods (Table II). Correlated against the day
number in each period (1–28), the fraction of subjects who
woke up due to coughing decreased during the Luna
period (P = 0.001, R = −0.57 Pearson CC) and increased
during the UC period (P = 0.003, R = +0.55 Pearson CC).
This effect was seen for Luna and UC in both group A and
group B (see Fig. 2) (P = 0.17 for Luna in group A, P < = 0.05
for all other curves).
The overall mean number of days in which subjects
reported at least one episode of disturbed sleep due to
coughing overnight did not differ between the UC and Luna
periods (UC: mean 8.3; median 2 [SD 10.7, range 0–28],
Luna: mean 7.2; median 3 [SD 9.4 range 0–28], P = 0.10).
Skin Irritation and Skin Improvement
Skin irritation was reported by 26 subjects at base-
line, 21 subjects during the UC, and 19 subjects during
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the Luna period. During the study, 12 subjects reported
skin irritation at multiple days per week (both UC and
Luna periods). The mean number of days when subjects
documented skin irritation in the evening did not differ
between the UC (mean: 6.6 [SD: 10.4], median: 0 [range:
0–28] days) and Luna (mean: 5.1 [SD: 7.9], median: 1 [range:
0–28] days, P = 0.338) periods. However, skin improvement
overnight was observed in a greater frequency of nights
during the Luna interval (Luna 29 subjects, mean: 8.1 [SD:
10.8], median: 2, range: [0–28] days, UC 17 subjects, mean:
3.9 [SD: 7.0], median: 0, range: [0–28] days, P = 0.012).
Only one of the 11 noncompliant subjects during the UC
period did not report skin improvement overnight at least
once. Both noncompliant subjects during the Luna period
reported skin improvement overnight. Of the eight subjects
who reported not using an HME every night at baseline, six
Fig. 1. Breakdown of the recruitment of subjects and the number of subjects who were included in the ﬁnal analysis. Erasmus MC = Erasmus
Medical Center; MUMC = Maastricht University Medical Center; NKI = National Cancer Institute. [Color ﬁgure can be viewed in the online
issue, which is available at www.laryngoscope.com.]
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reported skin improvement overnight at least once during
the Luna period and seven during the UC period.
During the Luna period and the UC period, there
was a difference between compliant versus noncompliant
subjects with regard to skin irritation (Luna: P = 0.03,
UC: P < 0.001, Wilcoxon two-sample test). Also, during
the UC period skin improvement overnight differed
between compliant and noncompliant subjects (Luna:
P = 0.13, UC: P < 0.001, Wilcoxon two-sample test). Here,
patients who were noncompliant reported less skin irrita-
tion. The number of nights during the Luna period when
there was no skin irritation during the day and an
improvement of the skin overnight (189 nights in n = 18
subjects) outnumbered those during the UC period
(51 nights in n = 7 subjects, P = 0.001 WMPSR).
Overall Subject Experience
At the ﬁnal evaluation, all 46 subjects were asked to
compare the Provox Luna system to that of their usual
care using a standardized questionnaire. Table III shows
the number of subjects who reported their comparative
experience with the Luna system under various outcome
categories. Signiﬁcantly improved subjective dermatologi-
cal experiences were observed, including 30% less episodes
of skin irritation (P = 0.03), 22% less severity of skin irrita-
tion (P > 0.05), and 33% shorter duration of skin irritation
(P = 0.05) with 28% better skin recovery (P = 0.008) with
Provox Luna system. Similarly, 35% of subjects reported a
more comfortable sleeping experience with the Provox
Luna system compared to their UC. However, no reported
difference was recorded for questions regarding patient-
reported differences in breathing and coughing.
The mean subject reported satisfaction score regard-
ing use of the Luna system (from 1–5) was 3.7  1.2.
Twenty-six (57%) subjects concluded they would continue
using the Provox Luna following the study: every night
(n = 19), 5 to 6 nights per week (n = 2), 3 to 4 nights per
TABLE II.
Comparison of Compliance, Coughing at Night, Skin Irritation, and
Skin Improvement Between UC and Luna Periods.
Outcome Measure
Usual Care
(n = 46)
Luna HME
(n = 45) P Value
Compliance
Overall number of compliant
individuals (n)
35 43 0.065
Mean (SD) hours of HME use per
day [range]
21.6 (4.3) 23.3 (1.4) 0.003
[6.0–24.0] [15.6–24.0]
Mean (SD) number of compliant
days [range]
22.5 (10.1) 27.0 (4.3) 0.025
[0–28] [0–28]
Weekly mean (SD) hours of HME use
per day [range]
Week 1 21.6 (4.2) 23.3 (1.4) 0.011
[0.9–24.0] [15.3–24.0]
Week 2 21.8 (3.9) 23.0 (2.0) 0.011
[8.4–24.0] [14.9–24.0]
Week 3 21.4 (4.6) 23.3 (1.5) 0.001
[4.9–24.0] [15.8–24.0]
Week 4 21.3 (4.1) 23.3 (1.5) 0.001
[5.6–24.0] [16.3–24.0]
P value 0.994 0.902
Overall mean number (SD) of nights
without HME use [range]
Bib use 2.5 (7.2) 0.1 (0.5) 0.013
[0–28.0] [0–3.0]
Exposed tracheostoma 2.2 (7.1) 0.1 (0.4) 0.058
[0–28.0] [0–2.0]
Coughing at Night
Mean (SD) number of episodes of
disturbed sleep due to coughing
per night [range]
0.50 (0.75) 0.49 (0.75) 0.537
[0–2.6] [0–2.6]
Mean number (SD) of days with at
least one episode of disturbed
sleep due to coughing at night
[range]
8.3 (10.7) 7.2 (9.4) 0.10
[0–28] [0–28]
Skin Irritation
Overall mean (SD) number of days
with skin irritation in the evening
[range]
6.6 (10.4) 5.1 (7.9) 0.347
[0–28] [0–28]
Skin Improvement
Overall mean (SD) number of days
with skin improvement overnight
[range]
3.9 (7.0) 8.1 (10.8) 0.008
[0–28] [0–28]
Luna HME: Atos Medical, Malmö, Sweden.
HME = heat and moisture exchanger; SD = standard deviation; UC =
usual care.
Fig. 2. Percentage of subjects with at least one episode of dis-
turbed sleep due to coughing for each day throughout the study
period. (A) Subjects randomized to Provox Luna (Atos Medical,
Malmö, Sweden) ﬁrst (n = 23) and (B) subjects randomized to Usual
Care ﬁrst (n = 23). Pearson CC = Pearson correlation. [Color ﬁgure
can be viewed in the online issue, which is available at www.
laryngoscope.com.]
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week (n = 3), and 1 to 2 nights per week (n = 2). Twenty
subjects (43%) did not wish to continue using the adhe-
sive due to lack of advantages (n = 7), having to change
adhesive more often (n = 6), adhesive not sticky enough
(n = 3) or too small (n = 1), expense (n = 1), and burning
feeling of the adhesive (n = 1).
The EQ-5D-5 L scores at baseline and after the UC
period improved signiﬁcantly (P = 0.017). However, improve-
ment after the Luna period was (just) not signiﬁcant
(P = 0.061) and no difference was found between EQ-5D-5 L
scores were found after either the UC versus the Luna period
(P = 0.443).
DISCUSSION
This multicenter randomized crossover trial compared
compliance, dermatological, and pulmonary outcomes when
the Provox Luna system during the night was added to the
UC in laryngectomized subjects. Analysis of the dataset
revealed a signiﬁcant improvement in compliance, mean
hours of daily use, and a greater frequency of days when
subjects reported skin improvement overnight during the
Luna period. From the results of this study, it emerges that
skin irritation is an important determinant of compliant
HME use overnight.
Although our results suggest that coughing might
reduce over time when the Luna HME and adhesive are
used, the increase in reported coughing observed over
time during the UC period indicates that there are other
study-speciﬁc factors involved. There is currently no sat-
isfactory explanation for these observed trends, but com-
pliant HME use might be a factor.
Compliance has been deﬁned in this study based on
HME use described previously.12 Some of the subjects in
this study used a bib at baseline and occasionally during
the test period. Bibs may be used by laryngectomies
because of the limited availability or insufﬁcient reim-
bursement of HMEs. However, the HME properties of
bibs crucially depend on their proper use because air
leaks diminish their efﬁcacy.18,26
At the conclusion of the study, 57% (n = 26) indi-
cated to continue using the Provox Luna system. The 43%
(n = 20) who were indicated not to further use it men-
tioned that they perceived no advantages or that they dis-
liked changing the adhesive more often. Difﬁculty in and
issues with frequency of replacement have been described
in several other HME studies.20,27
Although previous works have indeed correlated
improvements in pulmonary outcomes to categorical
improvements in duration of HME use,11,20 this study is
novel in that it evaluated the speciﬁc duration of HME use
per day in hours. This allowed for better characterization
of compliance outcomes. Historically, there has been vari-
ability in the deﬁnition of compliant or adherent use.11,27
This may have contributed to large range of reported non-
compliance rates in using HMEs from 48% to 82% of
TABLE III.
Subject Reported Overall Experience at Final Follow-up Visit Comparative Questionnaire in All Subjects Who Successfully Completed the
Study (n = 46).
Comparative Experience
Easier/Lower/
Less/Better Same
Harder/Higher/
More/Worse Not Available
Compared to my usual nighttime HME, breathing with Luna HME was: 9 24 7 6
Compared to my usual nighttime HME, breathing resistance of Luna
HME was:
8 26 6 6
Coughing off the HME with Luna, compared to my usual nighttime HME
was:
1 13 2 30
Coughing during the night with Luna, compared to my usual nighttime
HME was:
5 26 1 14
Mucus production during the night with Luna, compared to my usual
nighttime HME was:
7 29 1 9
Forced expectorations during the night with Luna, compared to my usual
nighttime HME was:
2 14 – 30
How did you sleep during the period of using Provox Luna, compared to
my usual HME was:
5 33 2 6
Comfort of sleep during night with Luna HME, compared to my usual
nighttime HME was:
14 21 5 6
Comfort of sleep during night with Luna Adhesive, compared to my usual
nighttime adhesive was:
14 19 6 7
The number of episodes of skin irritation during the period using Provox
Luna, compared to my usual care was:
14 28 4 –
The severity of the skin irritation during the period using Provox Luna,
compared to my usual care was:
10 32 4 –
Recovering of the skin during the period using Provox Luna, compared
to my usual care was:
15 28 3 –
The duration of the skin irritation during the period using Provox Luna,
compared to my usual care was:
13 28 4 1
Luna Adhesive: Atos Medical, Malmö, Sweden; Luna HME: Atos Medical, Malmö, Sweden; Provox Luna: Atos Medical, Malmö, Sweden.
HME = heat and moisture exchanger.
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subjects.11,20,21 This clinical investigation employed com-
pliant use as deﬁned by ≥20 hours per day in ≥24 days in
the 28-day period as previously described.12,13 This was
determined as an acceptable and achievable duration of
daily use after compensating for daily/weekly activities
that may commonly limit compliance.
Owing to the randomized crossover trial design of the
study, the subjects were their own controls, thus allowing
for meaningful comparison of compliance and preferences
of the subjects between the two periods. Subsequent analy-
sis of the order of randomization revealed no signiﬁcant
impact on all observable outcomes, suggesting that the
study design was appropriate for the comparative assess-
ment of HME use. Furthermore, long-term conclusions are
difﬁcult to draw from the short follow-up interval.
By comparing compliance in the two arms of the study
in which one arm testing a new product during the night,
the compliance in patients usually not wearing an HME
during the night automatically increases. This might be a
ﬂaw in the design. Also, receiving weekly follow-up and
stressing the compliant use creates a situation with an arti-
ﬁcially increased compliance. The compliance reported at
baseline, observed during the usual care period of 76%, is
higher than previously reported in the literature.11,20,21
This may have resulted from the increased subject education
in the participating centers where the importance of HME
use is stressed. HME use during a subject’s UC period in this
study may not reﬂect their baseline, and reporting bias may
be present. Results on compliance of this study must there-
fore be interpreted with caution.
CONCLUSION
This multicenter randomized crossover trial compared
compliance and the dermatological and pulmonary out-
comes of adding the Provox Luna system during the night
to UC in laryngectomized subjects. Signiﬁcant improve-
ments in compliance, hours of HME use per day, and skin
improvement overnight were observed with the Luna. More
than half of the patients wanted to continue using the
Luna. The Provox Luna system is a viable additive to a sub-
ject’s UC, especially in the setting of compliance concerns
and in subjects who desire dermatological relief overnight.
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